Investor Presentation under Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
JSLL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jeena Sikho Lifecare reported strong Q4FY26 results with revenue of Rs 215.55 crore (up 55% YoY) and full-year FY26 revenue of Rs 801.35 crore (up 71% YoY). The company operates 119 Ayurvedic healthcare centres (61 hospitals, 58 clinics) with 2,861 total beds across 23 states. Q4 EBITDA margin moderated to 36% from 45% in Q3 due to one-time provisions for labour code changes, ESOP costs, and year-end bonuses, though FY26 full-year EBITDA margin expanded significantly to 44% versus 30% in FY25. The company recommended a final dividend of Rs 4.50 per share. IPD volumes grew 65% to 40,454 patients and OPD volumes rose 69% to approximately 5.7 lakh patients in FY26. The business is split between healthcare services (48% of revenue) and Ayurvedic products (52%), with 3-year revenue CAGR of 58% and ROCE of 46%.
Strong growth trajectory continues with margin improvement for the full year, though Q4 saw expected seasonal moderation. The capital-light franchise model and expanding bed capacity support sustained volume growth. Dividend recommendation reflects management confidence in cash generation.